Core Insights - Monogram Technologies Inc. has received FDA clearance for its mBôs™ Total Knee Arthroplasty (TKA) System, marking a significant milestone for the company and its technology [4][9] - The company is set to conduct a groundbreaking clinical trial for autonomous saw-based robotic TKA surgeries on live patients, which is expected to demonstrate the potential of robotic precision in surgical procedures [5][9] - Monogram is preparing for initial placements of the mBôs system with key opinion leader surgeons in the U.S. and advancing patient enrollment for the clinical trial in India [6][10] Financial Performance - Research and development expenses decreased by 6% to $2.3 million in Q1 2025, compared to $2.4 million in the same quarter of the previous year [11] - Marketing and advertising expenses saw a significant decrease of 63%, dropping to $44,000 from $120,000 year-over-year [12] - General and administrative expenses were $1.0 million, slightly down from $1.1 million in the prior-year quarter, with a net loss of $3.2 million for Q1 2025, an improvement from a net loss of $3.5 million in Q1 2024 [13] Cash Position - As of March 31, 2025, cash and cash equivalents totaled $13.3 million, down from $15.7 million at the end of 2024, indicating a focus on capital efficiency in commercialization efforts [14] Upcoming Initiatives - The company plans to initiate patient enrollment for the clinical trial and begin the first live patient surgeries in India within 90 business days [9][10] - Monogram is also exploring additional domestic and international partnerships to support the commercialization of the mBôs TKA System [7][10]

Core Insights - Stereotaxis reported a 9% increase in revenue for Q1 2025, totaling $7.5 million compared to $6.9 million in Q1 2024, driven by a 29% growth in recurring revenue [3][8] - The company is focused on advancing its innovation strategy, with key commercial advances including the initial commercialization of MAGiC in Europe and successful demonstrations of the GenesisX robot [2][8] - Stereotaxis expects double-digit revenue growth for the full year 2025, with system revenue projected at $2-3 million per quarter and recurring revenue scaling to $7 million in Q4 2025 [8][9] Financial Performance - System revenue for Q1 2025 was $2.0 million, down from $2.6 million in Q1 2024, while recurring revenue reached $5.5 million, up from $4.3 million [3][13] - Gross margin for Q1 2025 was 54%, with recurring revenue gross margin at 68% and system gross margin at 15% [4][14] - Operating loss for Q1 2025 was ($5.9) million, compared to ($4.7) million in Q1 2024, with adjusted operating loss at ($2.7) million [6][14] Cash and Liquidity - As of March 31, 2025, Stereotaxis had cash and cash equivalents of $10.7 million and no debt [7][15] - The company anticipates reduced cash use in 2025 compared to 2024, supported by growing recurring revenue and stable operating expenses [9] Regulatory and Market Outlook - Stereotaxis is advancing multiple regulatory efforts with six active reviews and plans for additional submissions, aiming for significant adoption of GenesisX pending regulatory approval in the U.S. [2][8] - The company expects substantial growth in 2026, supported by anticipated regulatory milestones and initial commercial launches in 2025 [8]

ST. LOUIS, April 22, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will release financial results for its 2025 first quarter on Monday, May 12, 2025 at the close of the U.S. financial markets. The Company will host a conference call and webcast at 4:30 p.m. EST that day to discuss the Company's results and corporate developments. About Stereotaxis Stereotaxis (NYSE: STXS) is a pion ...

Core Insights - The LIBERTY® Endovascular Robotic System demonstrated successful robotic navigation in all cases, achieving a 100% success rate and meeting the primary endpoint of the ACCESS-PVI pivotal trial [1][8] - The system resulted in a 92% reduction in radiation exposure with no adverse device events reported, indicating its safety and efficacy [1][2][8] - The study was conducted at three leading medical centers in the U.S., showcasing the credibility of the results [1] Company Overview - Microbot Medical Inc. is a pre-commercial stage medical technology company focused on redefining endovascular robotics to enhance patient care globally [5] - The company has developed the first single-use, fully disposable endovascular robotic system, aiming to overcome traditional barriers in accessing advanced robotic systems [5] Clinical Study Highlights - The ACCESS-PVI study involved 20 cases, with a mean robotic navigation time to target of 3 minutes [8] - Participating physicians reported a 100% satisfaction rate with the performance of the LIBERTY® system [8] - The mean difference in radiation exposure between the operator and control was a reduction of 29.8 µS, confirming the system's effectiveness in minimizing radiation [8] Future Outlook - The company is preparing for the commercial launch of LIBERTY® and is confident in its market reception based on positive clinical data and feedback from investigators [4] - LIBERTY® is currently pending FDA 510(k) clearance and is not available for sale in the U.S. [4]